Amniotics

Amniotics is a biopharmaceutical company focused on amniotic fluid-derived mesenchymal stem cells (MSC). The company's inception began with the discovery of a new stem cell source in full-term amniotic fluid. Based on a decade of research conducted at the internationally recognized Lund University Stem Cell Center and Lund University Hospital, the company is pioneering the collection and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC). These cells possess unique properties that make them suitable for regenerative medicine research. Amniotics also owns an approved GMP (Good Manufacturing Practice) manufacturing facility for the production of advanced therapy medicinal products. This GMP facility has been operational since 2020, and Amniotics is currently advancing its lead candidate drug, PulmoStem™, into clinical trials. The company is seeking to establish strategic partnerships with research institutions and companies dedicated to developing cell-based therapies for diseases with unmet treatment needs. Amniotics is listed on the Nasdaq First North Growth Market in Stockholm.